Compare National Beverage Corp. (FIZZ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Spyre Therapeutics Inc. Common Stock — how do they compare? National Beverage Corp. trades at $33.54 (market cap $3.08B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.4× National Beverage Corp.'s market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 32 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FIZZ | SYRE | |
|---|---|---|
Market Cap | $3.08B | $7.52B |
Volume | 604,078 | 1,441,031 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $108.92 |
52-Week Low | $29.20 | $22.18 |
Typical Hold Time | 32 Days | 0 Days |
Enterprise Value | $3.04B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $33.54, up 4.32% with a bullish technical signal. The stock shows strong profitability with 14.81% net margins and 40.13% ROE, though recent quarters have seen earnings misses. Cash flow turned negative in 2025 due to significant financing outflows. Technical indicators suggest bullish momentum despite overbought RSI readings near 73.
FIZZ faces mixed sentiment with 50% analyst sell ratings but strong institutional interest. Revenue growth remains stagnant while margin pressure from input costs presents headwinds. The current valuation at 17.7x P/E appears reasonable given profitability, but execution risks and competitive pressures warrant caution for investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
